Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
There's the takeover king, who's interested only in snagging new assets, the pharma executive leading a major change in marketing practices, the regulator who's fostering a new approach to development and a high-profile R&D chief who's trying to piece together a new, more efficient method for drug development. And many others.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
This year's influentials report was truly a team effort. In addition to my own input, Tracy Staton, Eric Palmer and Carly Helfand selected individuals from the pharma world. Damian Garde and Emily Mullin made a big assist in biotech and research. Mark Hollmer looked at devices and diagnostics with Michael Gibney and Emily Wasserman lending a hand. And Managing Editor Galen Moore contributed and edited.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year.
-- John Carroll, editor-in-chief (email | Twitter)